European Journal of Cancer · 2018 · 71 citations · 20 references
PharmacyImmunologyClinical ImmunologyImmunotherapyCancer ImmunotherapyImmune System ToxicityImmune-related Adverse Event ManagementImmune-related Adverse EventsImmunotherapy SafetyPharmacodynamics Of ImmunotherapiesDose-limiting Toxicity AssessmentEarly-phase Clinical TrialsImmune-mediated Adverse EventsImmune-related Adverse Event AssessmentImmune-related Adverse Event GradingImmune-related Toxicity DetectionImmunotherapy Trials
20
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17